Merck & Co Inc (MRK)
127.51
-0.75
(-0.58%)
USD |
NYSE |
May 03, 16:00
127.59
+0.08
(+0.06%)
After-Hours: 20:00
Merck SG&A Expense (Quarterly): 2.483B for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 2.483B |
December 31, 2023 | 2.804B |
September 30, 2023 | 2.519B |
June 30, 2023 | 2.702B |
March 31, 2023 | 2.479B |
December 31, 2022 | 2.687B |
September 30, 2022 | 2.52B |
June 30, 2022 | 2.512B |
March 31, 2022 | 2.323B |
December 31, 2021 | 2.83B |
September 30, 2021 | 2.336B |
June 30, 2021 | 2.281B |
March 31, 2021 | 2.187B |
December 31, 2020 | 2.619B |
September 30, 2020 | 2.06B |
June 30, 2020 | 2.085B |
March 31, 2020 | 2.555B |
December 31, 2019 | 1.729B |
September 30, 2019 | 2.589B |
June 30, 2019 | 2.712B |
March 31, 2019 | 2.425B |
December 31, 2018 | 2.643B |
September 30, 2018 | 2.443B |
June 30, 2018 | 2.508B |
March 31, 2018 | 2.508B |
Date | Value |
---|---|
December 31, 2017 | 2.642B |
September 30, 2017 | 2.459B |
June 30, 2017 | 2.50B |
March 31, 2017 | 2.472B |
December 31, 2016 | 2.848B |
September 30, 2016 | 2.393B |
June 30, 2016 | 2.458B |
March 31, 2016 | 2.318B |
December 31, 2015 | 2.615B |
September 30, 2015 | 2.472B |
June 30, 2015 | 2.624B |
March 31, 2015 | 2.601B |
December 31, 2014 | 2.925B |
September 30, 2014 | 2.975B |
June 30, 2014 | 2.973B |
March 31, 2014 | 2.734B |
December 31, 2013 | 2.982B |
September 30, 2013 | 2.803B |
June 30, 2013 | 3.14B |
March 31, 2013 | 2.987B |
December 31, 2012 | 3.39B |
September 30, 2012 | 3.063B |
June 30, 2012 | 3.249B |
March 31, 2012 | 3.074B |
December 31, 2011 | 3.704B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.729B
Minimum
Dec 2019
2.83B
Maximum
Dec 2021
2.451B
Average
2.516B
Median
SG&A Expense (Quarterly) Benchmarks
Amgen Inc | 1.808B |
Johnson & Johnson | 5.057B |
Eli Lilly and Co | 1.836B |
Pfizer Inc | 3.495B |
Moderna Inc | 274.00M |